Computer simulations of bioequivalence trials: Selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 147-156

  Fernández Teruel, Carlos ^a   Gonzalez Alvarez, Isabel ^b   Navarro Fontestad, Carmen ^a   García Arieta, Alfredo ^c   Bermejo, Marival ^b   Casabó, Vicente G ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Facultad de Farmacia   (Spain)

^c Pharmacokinetics Service   (Spain)

Author keywords

BCS; Bioequivalence; First pass metabolism; Single dose; Steady state

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG METABOLISM; DRUG PENETRATION; FIRST PASS EFFECT; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STEADY STATE;

ALGORITHMS; ANIMALS; BIOPHARMACEUTICS; COMPUTER SIMULATION; HUMANS; INTESTINAL ABSORPTION; KINETICS; LIVER; NONLINEAR DYNAMICS; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 58149122682     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.023     Document Type: Article

References (21)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Blume H.H., and Midha K.K. Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 82 (1993) 1186-1189
3. Chen M.L., and Jackson A.J. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res. 8 (1991) 25-32
4. Chen M.L., and Jackson A.J. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect. Pharm. Res. 12 (1995) 700-708
5. el-Tahtawy A.A., Jackson A.J., and Ludden T.M. Comparison of single and multiple dose pharmacokinetics using clinical bioequivalence data and Monte Carlo simulations. Pharm. Res. 11 (1994) 1330-1336
6. el-Tahtawy A.A., Jackson A.J., and Ludden T.M. Evaluation of bioequivalence of highly variable drugs using Monte Carlo simulations. I. Estimation of rate of absorption for single and multiple dose trials using Cmax. Pharm. Res. 12 (1995) 1634-1641
7. el-Tahtawy A.A., Tozer T.N., Harrison F., Lesko L., and Williams R. Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II. Comparison of single and multiple-dose trials using AUC and Cmax. Pharm. Res. 15 (1998) 98-104
8. EMEA, 2001. CPMP/EWP/QWP/1401/98. Note for guidance on investigation of bioavailability and bioequivalence.
9. EMEA, 2006. CHMP/EWP/40326/2006. Efficacy Working Party. Questions and Answers on the Bioavailability and Bioequivalence Guideline, pp. 1-5.
10. Ezan E., Ardouin T., Delhotal Landes B., Flouvat B., Hanslik T., Legeai J.M., and Grognet J.M. Bioequivalence study of alpha-dihydroergocryptine: utility of metabolite evaluation. Int. J. Clin. Pharmacol. Ther. 34 (1996) 32-37
11. FDA, 2003. Guidance for industry bioavailability and bioequivalence studies for orally administered drug products-general considerations.
12. Jackson A.J. Prediction of steady-state bioequivalence relationships using single dose data I-linear kinetics. Biopharm. Drug Dispos. 8 (1987) 483-496
13. Jackson A.J. Prediction of steady state bioequivalence relationships using single dose data. II. Nonlinear kinetics. Biopharm. Drug Dispos. 10 (1989) 489-503
14. Jackson A.J. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect. Pharm. Res. 17 (2000) 1432-1436
15. Mahmood I. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite?. Int. J. Clin. Pharmacol. Ther. 36 (1998) 540-544
16. Rosenbaum S.E. Effects of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model. Pharm. Acta Helv. 73 (1998) 135-144
17. Rosenbaum S.E., and Lam J. Bioequivalence parameters of parent drug and its first-pass metabolite: comparative sensitivity to sources of pharmacokinetic variability. Drug Dev. Ind. Pharm. 23 (1997) 337-344
18. Tucker G.T., Rostami-Hodjegan A., and Jackson P.R. Bioequivalence-a measure of therapeutic equivalence?. In: Midha K.K., and Blume H.H. (Eds). Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics (1993), Medpharm Scientific Publishers, Stuttgart 35-43
19. Tucker G.T., Rostami-Hodjegan A., and Jackson P.R. Metabolite measurement in bioequivalence studies: theoretical considerations. In: Midha K.K., and Blume H.H. (Eds). Bio-International: Bioavailability, Bioequivalence and Pharmacokinetics (1993), Medpharm Scientific Publishers, Stuttgart 163-170
20. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
21. Zha J., and Endrenyi L. Variation of the peak concentration following single and repeated drug administrations in investigations of bioavailability and bioequivalence. J. Biopharm. Stat. 7 (1997) 191-204